STAT1 and acute graft versus host disease: This asserts that the anti-inflammatory effects of BRD4 inhibition are independent of STAT1, which is a target of the currently FDA approved Jak1/2 inhibitor, ruxolitinib, for steroid refractory acute GVHD.